Dimethyl Fumarate in the Management of Multiple Sclerosis: Appropriate Patient Selection and Special Considerations

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s85099
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis

Prescriber
Pharmacology
2014English

Nonfatal PML in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2016English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Dimethyl Fumarate Treatment Alters NK Cell Function in Multiple Sclerosis

European Journal of Immunology
AllergyImmunology
2017English

Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two-Year Experience

Multiple Sclerosis Journal – Experimental, Translational and Clinical
2017English

HDL-cholesterol Elevation Associated With Fingolimod and Dimethyl Fumarate Therapies in Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis

Frontiers in Immunology
AllergyImmunology
2019English

B-Cell Composition in the Blood and Cerebrospinal Fluid of Multiple Sclerosis Patients Treated With Dimethyl Fumarate

Multiple Sclerosis and Related Disorders
MedicineNeurology
2018English

Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases

Frontiers in Immunology
AllergyImmunology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy